CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is...
Phase 1
Berlin, Germany and 20 other locations
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...
Phase 2
Berlin, Germany and 53 other locations
or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic...
Phase 3
Berlin, Germany and 100 other locations
objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...
Phase 3
Berlin, Germany and 212 other locations
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic...
Phase 3
Berlin, Germany and 174 other locations
rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic...
Phase 3
Berlin, Germany and 153 other locations
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...
Phase 3
Berlin, Germany and 180 other locations
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have...
Phase 3
Berlin, Germany and 231 other locations
venetoclax versus obinutuzumab + chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medic...
Phase 3
Berlin, Germany and 111 other locations
This multicenter, prospective, open-label, randomized, superiority phase 3 study is designed to demonstrate that treatment with a triple combination...
Phase 3
Berlin, Germany and 29 other locations
Clinical trials
Research sites
Resources
Legal